Current status of rational design of prodrugs targeting the intestinal di/tri-peptide transporter hPEPT1 (SLC15A1)

Lasse Saaby, Carsten Uhd Nielsen, Bente Steffansen, SB Larsen, Birger Brodin

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

The intestinal di/tri-peptide transporter hPEPT1 has broad substrate specificity, accommodating uptake of the majority of investigated di- and tripeptides, as well as of a number of drug compounds. This transport system has a high capacity and it has been hypothesized that hPEPT1-mediated uptake of drug compounds, conjugated with promoieties so as to resemble di- or tripeptides, may be a strategy for increasing the intestinal permeability of compounds with otherwise low bioavailability. Based on the research activities of our group during the last decade, as well as on general research in the field, the present review aims at giving a brief overview of structure-activity relationships for hPEPT1, and to provide a critical evaluation of whether hPEPT1-targeted prodrugs can be rationally designed.
OriginalsprogEngelsk
TidsskriftJournal of Drug Delivery Science and Technology
Vol/bind23
Udgave nummer4
Sider (fra-til)307-314
ISSN1773-2247
DOI
StatusUdgivet - 2013
Udgivet eksterntJa

Fingeraftryk Dyk ned i forskningsemnerne om 'Current status of rational design of prodrugs targeting the intestinal di/tri-peptide transporter hPEPT1 (SLC15A1)'. Sammen danner de et unikt fingeraftryk.

Citationsformater